Evolving chemotherapeutics

Bridging trial underway

The bridging PK study of Deflexifol is reported to be progressing well. Sponsored by Detsamma Investments under an out-license from FivepHusion, the clinical trial is being undertaken at the Southern Medical Day Care Centre in Wollongong, Australia. Study chief investigator Associate Professor Daniel Brungs reports that patients are still being recruited to Dose Level 2, after the independent safety monitor reviewed the results from Dose Level 1 and approved an increase to the next dosing level. The study is expected to finish recruiting patients before the end 2020, and remains largely unaffected to date by the COVID-19 pandemic.